[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proton-pump-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proton-pump-inhibitor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100631957","optimizing-medications-and-lung-health-in-people-with-hiv-through-pharmacist-led-proactive-e-consults-100631957",false,"NCT07507435","Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults","Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)","Inclusion Criteria:\n\n* PWH on ART for 6 months, receiving care at the VA, and one or more of the following:\n\n  1. Actively smoking\n  2. Prescribed ICS for \\>90 days\n  3. Prescribed a PPI for \\>90 days\n\n     Exclusion Criteria:\n* Enrolled in palliative care or hospice\n* if a non-VA provider is the main primary care or HIV provider\n* Are currently participating in a separate ongoing interventional clinical trial","ALL","18 Years",{"count":19,"type":20},480,"ESTIMATED","INTERVENTIONAL",[23],"NA","People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs).\n\nOPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate.\n\nThe trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.",[26,27,28,29,30],"HIV","Inhaled Corticosteroid","Proton Pump Inhibitor","Smoking Cessation","Pneumonia",[32,33,26],"Pharmacist","E-consult","NOT_YET_RECRUITING","2026-03-26",{"date":37,"type":38},"2026-04-02","ACTUAL",{"date":40,"type":20},"2026-05",{"date":42,"type":20},"2029-09",{"name":44,"class":45},"Seattle Institute for Biomedical and Clinical Research","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100605663","potassium-competitive-acid-blocker-versus-proton-pump-inhibitor-as-a-part-of-bismuth-based-quadruple-therapy-for-treatment-of-helicobacter-pylori-infection-100605663","NCT07165444","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Both sexes.\n* Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).\n* No prior eradication therapy.\n\nExclusion Criteria:\n\n* Prior Helicobacter pylori treatment.\n* Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.\n* Gastric surgery history.\n* Major organ failure.\n* Pregnancy or lactation.\n* Known allergy to study drugs.",{"count":55,"type":20},320,[23],"This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.",[59,28,60,61,62],"Potassium-Competitive Acid Blocker","Bismuth Based Quadruple Therapy","Treatment","Helicobacter Pylori Infection","RECRUITING","2025-09-11",{"date":66,"type":38},"2025-09-12",{"date":64,"type":38},{"date":69,"type":20},"2026-02-01",{"name":71,"class":45},"Tanta University",1]